Table 1.
Characteristic | Patients (N = 187) |
---|---|
Age, years | |
Median | 64 |
Range | 24-88 |
Sex, % | |
Male | 75 |
Female | 25 |
Ethnicity, % | |
White | 63 |
African American | 12 |
Asian | 20 |
Hispanic | 4 |
Unknown | 1 |
Cirrhosis, % | |
Yes | 55 |
No | 45 |
Etiology, % | |
Hepatitis C | 30 |
Hepatitis B | 33 |
Alcohol | 30 |
Other | 14 |
None | 24 |
Symptoms, % | |
Present | 78 |
Absent | 22 |
ECOG PS, % | |
0-1 | 80 |
2-3 | 20 |
Abdominal pain, % | |
Yes | 34 |
No | 66 |
Weight loss, % | |
Yes | 33 |
No | 67 |
Ascites, % | |
Yes | 18 |
No | 82 |
Encephalopathy, % | |
Yes | 2 |
No | 98 |
Esophageal varices, % | |
Yes | 21 |
No | 73 |
Laboratory values, medians | |
Total bilirubin, mg/dL | 1.1 |
Albumin, g/dL | 3.2 |
PT | 1.06 |
Platelets, K/μL | 179 |
Alkaline phosphatase, U/L | 146 |
AST, U/L | 72 |
ALT, U/L | 45 |
AFP, ng/mL | 355 |
Total bilirubin, mg/dL | 1.1 |
Albumin, g/dL | 3.2 |
Liver function by Child-Pugh stage, % | |
A | 67 |
B | 29 |
C | 4 |
Tumor characteristic, % | |
No. of liver tumors | |
0 | 6 |
1-5 | 39 |
> 5 | 55 |
Diameter of largest lesion, cm | 6.7 |
Bilobar disease | |
Yes | 70 |
No | 30 |
Extent | |
≤ 50% | 70 |
> 50% | 30 |
Vascular invasion | |
Yes | 36 |
No | 64 |
Portal vein thromboses | |
Yes | 30 |
No | 70 |
Organ invasion | |
Yes | 4 |
No | 96 |
T | |
0-2 | 36 |
3-4 | 64 |
N | |
Yes | 37 |
No | 63 |
M | |
Yes | 60 |
No | 40 |
Previous treatment, % | |
No. of previous treatments | |
0 | 43 |
1 | 32 |
≥ 2 | 25 |
Surgery | 25 |
Embolization | 34 |
Ablation | 14 |
Chemoembolization | 6 |
Chemotherapy | 4 |
Transplantation | 1 |
Treatment offered, % | |
Clinical trial | 29 |
Chemotherapy | 33 |
Best supportive care | 38 |
Staging system | |
TNM* | |
1-2 | 6 |
2 | 32 |
3 | 63 |
Okuda stage | |
1 | 49 |
2 | 40 |
3 | 11 |
BCLC | 1 |
A | 1 |
B | 1 |
C | 85 |
D | 13 |
CLIP score | 9 |
0 | 9 |
1 | 19 |
2 | 31 |
3 | 23 |
4 | 12 |
5 | 6 |
CUPI | 38 |
Low | 38 |
Intermediate | 50 |
High | 12 |
JIS score | 0 |
0 | 0 |
1 | 2 |
2 | 8 |
3 | 64 |
4 | 22 |
5 | 3 |
GETCH | 15 |
Low | 15 |
Intermediate | 71 |
High | 14 |
Abbreviations: HCC, hepatocellular carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; PT, prothrombin time; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; CUPI, Chinese University Prognostic Index; JIS, Japan Integrated Staging; GETCH, Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.
Sixth edition.